XIAMEN, China – Tekwon (Tekwon Genetic Technologies Ltd.) is spearheading a landmark marine biopharmaceutical research initiative in collaboration with Xiamen University and Xiamen First Hospital, targeting key technological bottlenecks in shark peptide industrialization and clinical application.
The project has assembled an interdisciplinary team of more than ten leading researchers—including professors, senior engineers and PhDs. The team's expertise spans the entire pipeline, from basic research to clinical translation, ensuring strong support for the project. With a total budget of 1.2 million funded through a marine economy development grant, the three-year initiative aims to establish a complete industrial chain—from large-scale, high-purity production of shark-derived peptides to their clinical application. Upon success, the project is expected to yield the world’s first medical-grade peptide product derived from shark sources, marking a significant breakthrough in marine biopharmaceutical sector.
